Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia

Davide Rossi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Silvia Rasi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Giulia Fabbri(Cancer Genetics (United States)), Valeria Spina(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Marco Fangazio(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Francesco Forconi(University of Siena), Roberto Marasca(University of Modena and Reggio Emilia), Luca Laurenti(Università Cattolica del Sacro Cuore), Alessio Bruscaggin(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Michaela Cerri(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Sara Monti(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Stefania Cresta(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Rosella Famà(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Lorenzo De Paoli(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Pietro Bulian(Centro di Riferimento Oncologico), Valter Gattei(Centro di Riferimento Oncologico), Anna Guarini(Sapienza University of Rome), Silvia Deaglio(Italian institute for Genomic Medicine), Daniela Capello(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Raúl Rabadán(Columbia University), Laura Pasqualucci(Cancer Genetics (United States)), Riccardo Dalla‐Favera(Cancer Genetics (United States)), Robin Foà(Sapienza University of Rome), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”)
Blood
November 11, 2011
Cited by 453Open Access
Full Text

Abstract

Analysis of the chronic lymphocytic leukemia (CLL) coding genome has recently disclosed that the NOTCH1 proto-oncogene is recurrently mutated at CLL presentation. Here, we assessed the prognostic role of NOTCH1 mutations in CLL. Two series of newly diagnosed CLL were used as training (n = 309) and validation (n = 230) cohorts. NOTCH1 mutations occurred in 11.0% and 11.3% CLL of the training and validation series, respectively. In the training series, NOTCH1 mutations led to a 3.77-fold increase in the hazard of death and to shorter overall survival (OS; P < .001). Multivariate analysis selected NOTCH1 mutations as an independent predictor of OS after controlling for confounding clinical and biologic variables. The independent prognostic value of NOTCH1 mutations was externally confirmed in the validation series. The poor prognosis conferred by NOTCH1 mutations was attributable, at least in part, to shorter treatment-free survival and higher risk of Richter transformation. Although NOTCH1 mutated patients were devoid of TP53 disruption in more than 90% cases in both training and validation series, the OS predicted by NOTCH1 mutations was similar to that of TP53 mutated/deleted CLL. NOTCH1 mutations are an independent predictor of CLL OS, tend to be mutually exclusive with TP53 abnormalities, and identify cases with a dismal prognosis.


Related Papers

No related papers found

Powered by citation graph analysis